Ano Pharmaceuticals was awarded the "2020 China China Health Industry Innovation Award - Best Biopharmaceutical Innovation Enterprise"

The list of "Best Biopharmaceutical Innovation Enterprises" was released by the Edo think tank, which explores the core strength of the medical innovation process by taking the innovation of enterprise projects, product differentiation, performance growth, financing ability, market prospects, business model, product or service quality, brand awareness as reference, and including hard indicators such as establishment time, financing round and operating conditions.
Award, is the industry's recognition of the company's innovative strength and future development potential.
founded in Hangzhou, China, in 2016, Ano Pharmaceuticals has a research and development and clinical operations center in New Jersey, USA, which is located as a "global new" oncology drug, facing the global market, participating in global innovation, and its core team comes from the management of the world's top pharmaceutical companies, with extensive product development experience and international perspective.
currently, there are three clinically-staged drug candidates, including the FDA fast-track qualified AN2025 (buparlisib) project, which is in the process of global multi-center clinical phase 3; Global Multi-Center Clinical Phase 3 is being launched, the Global Potential FIC Oncology ImmunoAN0025 (EP4 Antagonist) project has completed a Phase 1b clinical trial in Europe and the United States as a new complementary therapy for the treatment of local late-stage rectal cancer, and a Phase IB trial in Europe and the United States in combination with Keytruda® to treat multiple solid tumors is under way.
in preclinical studies, Ano Pharma has accumulated a number of preclinical candidates represented by AN4005 (oral PD-L1) and AN3025 (TNFR2 antibodies).
Ano Pharmaceuticals' strategic vision and product pipeline for global innovation has been widely recognized by the industry, and the company has cooperated with top international pharmaceutical companies such as Merca East, Novartray Group, Japan's Wessau and Oncolytics.
the future, Ano Pharma will continue to focus on and accelerate the development of internationally competitive first innovative drugs to address clinically unsolved needs and turn cancer into a non-fatal disease and even a cure.
.